Type 2 diabetes and cognitive dysfunction—towards effective management of both comorbidities

This Series paper aims to synthesise knowledge about the link between diabetes and cognitive dysfunction, issues pertaining to screening and diagnosis, management of diabetes (accounting for age and frailty), and emerging therapies for prevention.

SPS commentary:

This is the second in a Series of papers about diabetes and brain health to be published in conjunction with The Lancet Neurology. The first paper highlights the role of insulin action in brain and its consequences on peripheral metabolism and cognition, suggesting improved central insulin action could represent a therapeutic option for people at increased risk of developing metabolic and cognitive diseases. The third paper published in Lancet Neurology shows how biomarker approaches can shed light on the complex causes of diabetes-associated cognitive dysfunction, focusing on type 2 diabetes.


The Lancet Diabetes & Endocrinology

Resource links:

First paper

Third paper